"Commenting on his appointment Mr Facchina said “My fellow principals at SurgCenter and I are very
excited about the future potential for Mesoblast across the breadth of its platform technology from
chronic heart failure and inflammatory bowel disease to the potential treatment for chronic low back
pain. I welcome the opportunity to make a significant contribution to the success in bringing these
potential treatments to market and look forward to working with the Board and management team.”
Ann: Director Appointment/Resignation, page-5
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
0.000(0.00%) |
Mkt cap ! $1.244B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.12 | $1.09 | $668.3K | 606.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 5253 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 6776 | 4 |
View Market Depth
| Last trade - 10.25am 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |